公开(公告)号：US20160368904A1

公开(公告)日：2016-12-22

申请号：US14902202

申请日：2014-07-03

Applicant: KARYOPHARM THERAPEUTICS INC.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  William Senapedis ,  Dilara McCauley ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: C07D405/14 ,  C07D307/81 ,  C07D409/14 ,  C07D491/048 ,  C07D413/14 ,  C07D417/12 ,  C07D491/08 ,  C07D405/12 ,  C07D413/12

CPC classification number: C07D405/14 ,  C07D307/81 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D491/048 ,  C07D491/08

Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (A), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

Abstract translation: 本发明一般涉及取代的苯并呋喃基和取代的苯并恶唑基化合物，更具体地涉及由结构式（A）表示的化合物或其药学上可接受的盐，其中变量如本文所定义和描述。 本发明还包括结构式（A）的化合物或其药学上可接受的盐或组合物的合成和用途，例如用于治疗癌症（例如，外套细胞淋巴瘤）和其它疾病和病症。

公开(公告)号：US12291508B2

公开(公告)日：2025-05-06

申请号：US18244659

申请日：2023-09-11

Applicant: Karyopharm Therapeutics Inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Dilara McCauley ,  Sharon Shechter

IPC: C07D249/08 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D241/20 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I. or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

公开(公告)号：US20240376114A1

公开(公告)日：2024-11-14

申请号：US18526900

申请日：2023-12-01

Applicant: Karyopharm Therapeutics Inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Michael Kauffman ,  Sharon Shechter ,  Dilara McCauley ,  Yosef Landesman ,  William Senapedis ,  Jean-Richard Saint-Martin

IPC: C07D487/10 ,  C07D213/50 ,  C07D401/06 ,  C07D401/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

公开(公告)号：US11787771B2

公开(公告)日：2023-10-17

申请号：US17321029

申请日：2021-05-14

Applicant: Karyopharm Therapeutics inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Dilara McCauley ,  Sharon Shechter

IPC: C07D249/08 ,  A61K31/497 ,  C07D241/20 ,  C07D403/12 ,  C07D401/12 ,  C07D409/12 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/498 ,  A61K31/506 ,  A61K31/55 ,  A61K31/496 ,  A61K31/5377

CPC classification number: C07D249/08 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D241/20 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I:




or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

公开(公告)号：US20220177445A1

公开(公告)日：2022-06-09

申请号：US17409150

申请日：2021-08-23

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  Dilara McCauley ,  Trinayan Kashyap ,  William Senapedis ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: C07D401/06 ,  C07D249/08 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

公开(公告)号：US20220073478A1

公开(公告)日：2022-03-10

申请号：US17321029

申请日：2021-05-14

Applicant: Karyopharm Therapeutics Inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Dilara McCauley ,  Sharon Shechter

IPC: C07D249/08 ,  A61K31/497 ,  C07D241/20 ,  C07D403/12 ,  C07D401/12 ,  C07D409/12 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/498 ,  A61K31/506 ,  A61K31/55 ,  A61K31/496 ,  A61K31/5377

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

公开(公告)号：US20210403459A1

公开(公告)日：2021-12-30

申请号：US17205797

申请日：2021-03-18

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  William Senapedis ,  Dilara McCauley ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: C07D405/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D307/81 ,  C07D413/14 ,  C07D491/048 ,  C07D491/08

Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

公开(公告)号：US20200339521A1

公开(公告)日：2020-10-29

申请号：US16696702

申请日：2019-11-26

Applicant: Karyopharm Therapeutics Inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Dilara McCauley ,  Sharon Shechter

IPC: C07D249/08 ,  A61K31/497 ,  C07D241/20 ,  C07D403/12 ,  C07D401/12 ,  C07D409/12 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/498 ,  A61K31/506 ,  A61K31/55 ,  A61K31/496 ,  A61K31/5377

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

公开(公告)号：US20200087313A1

公开(公告)日：2020-03-19

申请号：US16394986

申请日：2019-04-25

Applicant: Karyopharm Therapeutics Inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Michael Kauffman ,  Sharon Shechter ,  Dilara McCauley ,  Yosef Landesman ,  William Senapedis ,  Jean-Richard Saint-Martin

IPC: C07D487/10 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D401/08 ,  C07D401/12 ,  C07D403/14 ,  C07D413/12 ,  C07D403/06 ,  C07D401/06 ,  C07D213/50

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

公开(公告)号：US10544108B2

公开(公告)日：2020-01-28

申请号：US16203181

申请日：2018-11-28

Applicant: Karyopharm Therapeutics Inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Dilara McCauley ,  Sharon Shechter

IPC: A61K31/497 ,  C07D249/08 ,  A61K31/55 ,  A61K31/454 ,  A61K31/498 ,  A61K31/506 ,  A61K31/4196 ,  C07D401/12 ,  C07D241/20 ,  A61K31/5377 ,  A61K31/496 ,  C07D409/12 ,  C07D403/12 ,  A61K31/4439

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.